Monopar Therapeutics (MNPR) R&D In Process (2017)
Monopar Therapeutics (MNPR) has disclosed R&D In Process for 1 consecutive years, with $14.5 million as the latest value for Q3 2017.
- Quarterly R&D In Process changed N/A to $14.5 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2018, changed N/A year-over-year, with the annual reading at $14.5 million for FY2017, N/A changed from the prior year.
- R&D In Process hit $14.5 million in Q3 2017 for Monopar Therapeutics.
- In the past five years, R&D In Process ranged from a high of $14.5 million in Q3 2017 to a low of $14.5 million in Q3 2017.